A phase II study in metastatic NSCLC patients with EGFR mutations found no significant difference in median progression-free survival between those receiving emibetuzumab plus erlotinib and those receiving erlotinib alone [140]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.